Health
Regeneron’s Antibody Combination Therapy Reduces COVID-19 Mortality Risk – BioPharm International
RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for…
Results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial have shown that Regenerons investigational antibody combination therapy reduces the mortality risk for hospitalized patients with severe COVID-19 whose immune response has not started…
Continue Reading
-
Noosa News22 hours agoPotato mop-top virus detected at four more Tasmanian properties, including research plot
-
General24 hours agoBruce Lehrmann’s defence applies for messages allegedly sent to rape complainant by Network Ten lawyer in defamation case
-
General22 hours ago‘I love Australian people’: Iran ambassador speaks out
-
Noosa News24 hours agoThe ‘architect of modern Queensland’ farewelled in Brisbane